LX-2343 is a neuroprotective agent for the treatment of Alzheimer's disease. LX2343 ameliorates cognitive dysfunction in APP/PS1 transgenic mice via both Aβ production inhibition and clearance...
LXS-196 is an orally available protein kinase C (PKC) inhibitor with potential immunosuppressive and antineoplastic activities. Upon oral administration, LXS-196 binds to and inhibits PKC, which...
LX-4211 is a potent dual sodium-glucose cotransporter (SGLT)1 and SGLT2 inhibitor and an anti-diabetic agent. Sotagliflozin significantly improves glycemic control, without increasing the rate of...